Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis;Correlación entre las pruebas de sensibilidad in vitro a los antifúngicos y la evolución clínica de los pacientes con candidiasis y criptococosis

Revista Espanola de Quimioterapia

Volumn 15, Issue 1, 2002, Pages 32-42

  Viudes, A ^a   Canton E ^a   Peman J ^a   Lopez Ribot J L ^a   Gobernado, M ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Amphotericin B; Antifungal drug; Correlation; Fluconazole; Flucytosine; In vitro susceptibility; Yeast

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE;

ANTIBIOTIC SENSITIVITY; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CORRELATION ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG ABSORPTION; DRUG DISTRIBUTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; OUTCOMES RESEARCH; REFERENCE VALUE; REVIEW; STANDARDIZATION; HUMAN; MICROBIOLOGICAL EXAMINATION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; CRYPTOCOCCOSIS; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0036272749     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (82)

1. Impact of the changing epidemiology of fungal infections in the 1990s
2. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System
3. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
4. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis
5. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients
6. Clinical relevance of antifungal resistance
7. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
8. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections
9. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine
10. Quality control guidelines for National Committee for Clinical Laboratory Standards - Recommended broth macrodilution testing of ketoconazole and itraconazole
11. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance
12. Detection of amphotericin B-resistant Candida isolates in a brothbased system
13. Comparison of E -test and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
14. Susceptibility testing of fungi and correlation with clinical outcome
15. Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis
16. Antifungal susceptibility testing: Technical advances and potential clinical applications
17. High-dose fluconazole therapy in patients with severe fungal infections
18. Actualización de las asociaciones de los antifúngicos sistémicos
19. Actividad de las asociaciones de los antifúngicos sistémicos
20. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia
21. Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital
22. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
23. Characterization and quantition of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
24. Timed-killing curves for Cryptococcus neoformans isolated from patients with AIDS
25. Pharmacokinetics of fluconazole in pediatric patients
26. Susceptibility testing of fungi: Current status of correlation of in vitro data with clinical outcome
27. Resistance of Candida species to fluconazole
28. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
29. Itraconazole cyclodextrin solution: The role of in vitro susceptibility testing in predicting successful treatment of HIV-related fluconazole-resistant and fluconazole-susceptible oral candidiasis
30. Response to fluconazole by 23 patients with human immunodeficiency virus infection and oral candidiasis: Pharmacological and mycological factors
31. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS
32. Correlation of in-vitro susceptibility test results with clinical response: A study of azole therapy in AIDS patients
33. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidiasis and human immunodeficiency virus infection
34. Comparative evaluation of three antifungal susceptibility test methods for Candida albicans isolates and correlation with response to fluconazole therapy
35. Epidemiology of oral candidiasis in HIV-infected patients: Colonization, infection, treatment, and emergence of fluconazole resistance
36. Fluconazole resistance in AIDS patients
37. Fluconazole-resistant candidiasis in an HIV cohort
38. Genetic dissimilarity of two fluconazole-resistant Candida albicans strains causing meningitis and oral candidiasis in the same AIDS patient
39. Fluconazole- resistant Candida albicans
40. Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus
41. Fluconazole-resistant Candida in AIDS patients. Report of two cases
42. DNA subtypes and fluconazole susceptibilities of Candida albicans isolates from the oral cavities of patients with AIDS
43. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis
44. Is antifungal susceptibility testing useful in guiding fluconazole therapy?
45. Clinical correlates of antifungal macrodilution susceptibility test results for non-AIDS patients with severe Candida infections treated with fluconazole
46. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
47. Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: The role of antifungal susceptibility testing
48. Fluconazole susceptibility testing of Cryptococcus neoformans: Comparison of two broth microdilution methods and clinical correlates among isolates from Ugandan AIDS patients
49. Correlation of fluconazole MIC with clinical outcome in cryptococcal infection
50. Unresponsive HIV-related oro-oesophageal candidiasis - An evaluation of two new in-vitro azole susceptibility tests
51. Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: Multilocus enzyme electrophoresis analysis and antifungal susceptibilities
52. Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
53. Azole drug resistance in yeasts
54. Itraconazole cyclodextrin solution - Effective treatment for HIV-related candidiasis unresponsive to other azole therapy
55. In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus
56. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species
57. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
58. Development of amphotericin B- resistant Candida tropicalis in a patient with defective leukocyte function
59. Development of resistance to amphotericin B in Candida lusitaniae infecting a human
60. Isolation and characterization of a polyene-resistant variant of Candida tropicalis
61. Antifungal susceptibility testing
62. Detection of resistance to amphotericin B in Candida isolates by using Iso-sensitest broth
63. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study
64. Correlation of in vitro susceptibility test results with in vivo response: Flucytosine therapy in a systemic candidiasis model
65. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis
66. Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1
67. Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients
68. Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole
69. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS
70. Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole
71. Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients
72. Treatment and secondary prophylaxis with fluconazole for oropharyngeal candidiasis in HIV-positive patients. A mycological analysis of failures
73. Susceptibilities of Norwegian Candida albicans strains to fluconazole: Emergence of resistance. The Norwegian Yeast Study Group
74. Evaluation of the E-test for fluconazole susceptibility testing of Candida albicans isolates from oropharyngeal candidiasis
75. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients
76. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations
77. Oropharyngeal candidiasis in patients with human immunodeficiency virus: Correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression
78. Amphotericin B-resistant yeast infection in severely immunocompromised patients
79. Correlation between in vitro susceptibility determined by E-test and response to therapy with amphotericin B: Results from a multicenter prospective study of candidemia
80. Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome
81. Amphotericin B-resistant Cryptococcus neoformans in a patient with AIDS